Desentum is a Finnish-based biopharmaceutical firm that has raised 8 million euros to fund a candidate for an allergy vaccine.
Springvest Oyj arranged the round.
The funds will be used by the company to fund further clinical research, R&D for new hypoallergens, and business development.
Desentum, headed by Pekka Mattila (CEO), develops new immunotherapeutic hypoallergens. These are also known as allergy vaccines. These hypoallergens, which are biotechnologically made modified allergen proteins, have been developed to improve allergen immunotherapy efficiency and reduce the treatment time. A First-in-Human clinical trial has been conducted on birch pollen hypoallergen DM101, the lead product candidate. DM-101 was well tolerated and safe with all the tested dosing regimes. Immunological marker results showed a positive change in markers that are associated with a protective reaction.
Desentum was founded in 2011 as a spin-off from VTT Technical Research Centre of Finland Ltd.